Skip to content

Zymeworks ZYME Pre-Tax Income (Domestic)

Pre-Tax Income (Domestic) at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$47.12M+0.5%
Charles River Laboratories logo
Charles River LaboratoriesCRL
-$72.66M-0.1%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$43.16M+376%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic.

The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's pre-tax income (domestic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's pre-tax income (domestic)?
Zymeworks (ZYME) reported pre-tax income (domestic) of -$4.2M in Q4 2025.
What does pre-tax income (domestic) mean?
The pre-tax earnings or losses generated specifically from business operations within the company's home country. This metric isolates domestic profitability, excluding the impact of international tax jurisdictions and non-recurring items. It helps investors assess the core performance of the domestic business engine.